Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E2 in patients treated with NSAIDs before vitrectomy.
A total of 0.5 to 1 mL undiluted vitreous was removed from the midvitreous cavity at the beginning of the surgery before infusion with balanced salt solution. Samples were immediately frozen and stored at -40°C until analysis. Samples were evaluated in a masked fashion. Vitreous concentrations of the study drugs were quantified using a reverse-phase liquid chromatography mass spectroscopy system. The minimum quantification limit for ketorolac, bromfenac, nepafenac, and amfenac was 0.8 ng/mL. Prostaglandin E2 concentrations were determined using a commercially available competitive enzyme immunoassay kit (R & D Systems, Minneapolis, MN).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | No Intervention | No NSAIDs were administered prior to surgery | |
| Ketorolac eyedrops | Experimental | Ketorolac 0.5% eyedrops were administered prior to surgery |
|
| Indomethacin eyedrops | Experimental | Indomethacin 0.5% eyedrops were administered prior to surgery |
|
| Nepafenac eyedrops | Experimental | Nepafenac 0.1% eyedrops were administered prior to surgery |
|
| Bromfenac eyedrops | Experimental | Bromfenac 0.09% eyedrops were administered prior to surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketorolac 0.5% eyedrops | Drug |
| ||
| Indomethacin 0.5% eyedrops |
| Measure | Description | Time Frame |
|---|---|---|
| Prostaglandin E2 levels in the vitreous (pg/mL) | 7 days after NSAID TID administration, following vitrectomy |
| Measure | Description | Time Frame |
|---|---|---|
| NSAIDs concentration (ng/mL) into the vitreous | Vitreous concentrations of the study drugs were quantified using a reverse phase high performance liquid chromatography mass spectroscopy system. | 7 days after NSAID TID administration, following vitrectomy |
| Adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33595256 | Derived | Morescalchi F, Russo A, Semeraro F. SURGICAL OUTCOMES OF VITREOMACULAR TRACTION TREATED WITH FOVEAL-SPARING PEELING OF THE INTERNAL LIMITING MEMBRANE. Retina. 2021 Oct 1;41(10):2026-2034. doi: 10.1097/IAE.0000000000003139. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020910 | Ketorolac |
| D009883 | Ophthalmic Solutions |
| D007213 | Indomethacin |
| C053083 | bromfenac |
| C414203 | nepafenac |
| ID | Term |
|---|---|
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Bromfenac 0.09% eyedrops | Drug |
|
| Nepafenac 0.1% eyedrops | Drug |
|
| 7 days after NSAID TID administration, following vitrectomy |
| D019999 | Pharmaceutical Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D020313 | Specialty Uses of Chemicals |